Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2014. The report details a specific share repurchase transaction executed on February 17, 2014, in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 30,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,688.00 pence per share; lowest price paid was 1,668.00 pence per share.
- Treasury Holdings (Settled): 488,666,169 shares, representing 9.14% of total issued share capital.
- Treasury Holdings (Including Unsettled): 488,696,169 shares, representing 10.06% of total voting rights.
- Shares in Issue (Excluding Treasury): 4,857,313,212 shares.
Material Changes
The filing reports a material change in the company's treasury stock position following the purchase of 30,000 shares. This transaction increased the percentage of total voting rights held in treasury to 10.06% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a routine disclosure of a share buyback transaction compliant with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in treasury (488,666,169 settled) against the company's latest capitalization table.
- Confirm the calculation of voting rights (10.06% including unsettled shares) for disclosure threshold assessments.
- Check the remaining authorization for share buybacks under the mandate granted on May 1, 2013.
- Note that this filing does not contain operational or financial performance data for the period.